Cargando…
Low oxygen tension reverses antineoplastic effect of iron chelator deferasirox in human glioblastoma cells
BACKGROUND: Overcoming resistance to treatment is an essential issue in many cancers including glioblastoma (GBM), the deadliest primary tumor of the central nervous system. As dependence on iron is a key feature of tumor cells, using chelators to reduce iron represents an opportunity to improve con...
Autores principales: | Legendre, Claire, Avril, Sylvie, Guillet, Catherine, Garcion, Emmanuel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4736662/ https://www.ncbi.nlm.nih.gov/pubmed/26832741 http://dx.doi.org/10.1186/s12885-016-2074-y |
Ejemplares similares
-
Pharmacogenetic Study of Deferasirox, an Iron Chelating Agent
por: Lee, Ji Won, et al.
Publicado: (2013) -
A role for ceruloplasmin in the control of human glioblastoma cell responses to radiation
por: Roy, Charlotte, et al.
Publicado: (2022) -
Iron Chelation Therapy with Deferasirox in the Management of Iron Overload in Primary Myelofibrosis
por: Elli, Elena Maria, et al.
Publicado: (2014) -
Effects of an oral iron chelator, deferasirox, on advanced hepatocellular carcinoma
por: Saeki, Issei, et al.
Publicado: (2016) -
From Biology to Clinical Practice: Iron Chelation Therapy With Deferasirox
por: Palumbo, Giuseppe A., et al.
Publicado: (2021)